Related references
Note: Only part of the references are listed.Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort
Roberto Iacovelli et al.
EUROPEAN JOURNAL OF CANCER (2013)
Targeted Therapies and Survival: What We Can Learn from Studies in Advanced Renal Cell Carcinoma
Giuseppe Procopio et al.
ONCOLOGY (2013)
A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
Frank Stenner et al.
ONCOLOGY (2012)
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
G. Procopio et al.
BRITISH JOURNAL OF CANCER (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Evaluation of Response in Malignant Tumors Treated With the Multitargeted Tyrosine Kinase Inhibitor Sorafenib: A Multitechnique Imaging Assessment
Olga Maksimovic et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2010)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib:: Pilot study using dynamic contrast-enhanced Doppler ultrasound
Michele Lamuraglia et al.
EUROPEAN JOURNAL OF CANCER (2006)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)